David Bredt's Planned Sale of Rapport Therapeutics Common Stock

David Bredt, an officer of Rapport Therapeutics, Inc., has filed a Form 144 notice indicating his intention to sell 25,500 shares of common stock acquired as Founder Shares. The shares were acquired between December 9, 2022, and March 9, 2023. The planned sale is scheduled for October 15, 2025, with an aggregate market value of $634,440. Additionally, Bredt has sold 17,000 shares in the past three months, generating gross proceeds of $333,114.15. The sales were executed under a 10b5-1 trading plan, which allows insiders to sell shares at predetermined times to avoid accusations of insider trading. The shares are traded on NASDAQ, and the transactions were facilitated by Morgan Stanley Smith Barney LLC Executive Financial Services.